Even though the results from the Checkmate143 clinical trial did not show survival differences in recurrent GBM patients treated with adjuvant anti-PD-1 therapy [100], recent work from our group suggests that a fraction of these patients have better responses to this immunotherapy assessed by the abundance of p-ERK in tumor regions. This evidence concerns the gene PDCD1 and neoplasm.